Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02252146
Title Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88L265P Mutation
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Idera Pharmaceuticals, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
UCLA Medical Center Los Angeles California 90095 United States Details
Emory University Atlanta Georgia 30306 United States Details
Cancer Care Specialists of Illinois Decatur Illinois 62526 United States Details
Horizon Bio Advance Lafayette Indiana 47905 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Mayo Clinic Rochester Minnesota 55905 United States Details
Washington University Saint Louis Missouri 63110 United States Details
Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
Columbia University Medical Center New York New York 10019 United States Details
Cleveland Clinic Cleveland Ohio 44109 United States Details
Vanderbilt Ingram Cancer Center Nashville Tennessee 37232 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field